⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689719 | 0.93 | — | — | |
| SCHEMBL16689738 | 0.92 | — | — | |
| SCHEMBL26247893 | 0.91 | — | — | |
| SCHEMBL16689717 | 0.88 | — | — | |
| SCHEMBL17903242 | 0.86 | — | — | |
| SCHEMBL26306380 | 0.85 | — | — | |
| SCHEMBL16248691 | 0.84 | TSHR (0.33) | — | |
| SCHEMBL25456954 | 0.84 | — | — | |
| SCHEMBL25456962 | 0.84 | — | — | |
| SCHEMBL12589448 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170183661-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170159055-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-9382540-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160090596-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160090595-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160076030-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160076032-A1 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9181549-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |